Mohammad Abbasinazari

Prof. Mohammad Abbasinazari


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
FDFarzaneh Dastan
Farzaneh Dastan
AAAhmad Ameri
Ahmad Ameri
SDSamaneh Dodge
Samaneh Dodge
HSHadi Hamidi Shishvan
Hadi Hamidi Shishvan
APAli Pirsalehi
Ali Pirsalehi
MAMohammad Abbasinazari
Mohammad Abbasinazari
Aim and Background Propolis has been used for the management of oral mucositis in a number of studies. Due to lack of sufficient evidence especially in radiotherapy induced oral mucositis, the present study was designed to evaluate the efficacy and safety of propolis mouthwash in oral mucositis and dysphagia in patients undergoing head and neck radiotherapy. Materials and methods This study was a prospective, randomised, double-blind, placebo-controlled trial. The patients randomly divided into two groups receiving either the propolis or the placebo mouthwash. Patients were advised to rinse their mouth with 15 mL three times daily for four weeks. Severity of mucositis and dysphagia were evaluated by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) and Common Terminology Criteria for Adverse Events (CTCAE), respectively. Results: Thirty patients completed the study. Each group consisted of 15 patients. Although, there is not any significant difference between two groups in the first week of radiotherapy, a significant difference was seen in the second, the third and the fourth week (p = 0.03, 0.02, 0.02, respectively). Dysphagia reported as a mild score in the propolis group only in the fourth week which is significant compared with the placebo group (p = 0.01). There is not any serious adverse effect related to propolis or placebo during the study. Conclusion: It seems that propolis mouthwash is an effective and safe medication for alleviation of oral mucositis and dysphagia in patients under head and neck radiotherapy.

1 June 2015 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
MAMohammad Abbasinazari
Mohammad Abbasinazari
LALadan Adib-Eshgh
Ladan Adib-Eshgh
ARAzin Rostami
Azin Rostami
NBNarges Beyraghi
Narges Beyraghi
SDShideh Dabir
Shideh Dabir
RJReyhaneh Jafari
Reyhaneh Jafari

1 April 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
NSNazanin Sarraf
Nazanin Sarraf
TBTaleb Badri
Taleb Badri
NKNegin Keshvari
Negin Keshvari
AGAyfar Ghassab-Sahebkar
Ayfar Ghassab-Sahebkar
RQRoja Qobadighadikolaei
Roja Qobadighadikolaei
MAMohammad Abbasinazari
Mohammad Abbasinazari

1 January 2012
Verified
Journal Article
Closed access
MAMohammad Abbasinazari
Mohammad Abbasinazari
SZSamaneh Zareh-Toranposhti
Samaneh Zareh-Toranposhti
AHAbdollah Hassani
Abdollah Hassani
MSMohammad Sistanizad
Mohammad Sistanizad
HAHoma Azizian
Homa Azizian
YPYunes Panahi
Yunes Panahi

1 March 2021
Verified
Journal Article
Open access
PDF file
SSShabnam Shahrokh
Shabnam Shahrokh
RQRoja Qobadighadikolaei
Roja Qobadighadikolaei
MAMohammad Abbasinazari
Mohammad Abbasinazari
MHMehrdad Haghazali
Mehrdad Haghazali
HAHamid Asadzadeh Aghdaei
Hamid Asadzadeh Aghdaei
MZMohammad Reza Zali
Mohammad Reza Zali
Ulcerative colitis (UC) is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. The exact etiology of UC is unknown, but the role of autoimmunity and activated inflammatory cascade is quite clear. Melatonin possesses anti-inflammatory and immune-modulative properties in animal and clinical trials. The aim of the present study was to evaluate the efficacy and safety of oral melatonin as an adjudicative therapy in clinical, biochemical, and quality of life in UC patients. Thirty patients diagnosed with mild to moderate UC, were randomly allocated to either receive melatonin (3 mg/d) or the placebo group for three months. Simple clinical colitis activity index (SCCAI), fecal calprotectin (FC), C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Sf-36 questionnaire have been used for assessment at the baseline and the end of the trial. Melatonin significantly improve SCCAI score, FC, role-emotional, energy and general health relative to placebo (p = 0.03, 0.05, 0.002, 0.032, 0.004 respectively). Regarding CRP, ESR, and the other components of SF-36 there is not any significant difference between melatonin and placebo group. Melatonin supplementation over a three-month period is effective and safe in improving clinical index, FC, and some quality of life in patients with mild to moderate UC.

1 January 2021
Verified
Open access
SASaeed Abdi
Saeed Abdi
MAMohammad Abbasinazari
Mohammad Abbasinazari
SASara Ataei
Sara Ataei
NKNeda Khanzadeh-Moghaddam
Neda Khanzadeh-Moghaddam
NKNegin Keshvari
Negin Keshvari
Melatonin is the "clock factor" produced from the pineal gland dominating regular circadian rhythm in mammalians. It is an indoleamine with potent multifunctional pharmacological effects, both receptor dependent and non-receptor dependent effects, including antioxidant and anti-inflammatory activities. The aim of this review is to summarize clinical evidence related to melatonin's effectiveness in the treatment of liver and pancreas diseases. Databases including PubMed, Scopus, and Cochran Library were searched up to November 2020.Finally, this review has summarized up-to-date clinical evidence to investigate the efficacy and safety of melatonin for the management of liver and pancreas diseases. Melatonin has been demonstrated to have beneficial effects on the management of Non-alcoholic fatty liver disease (NAFLD), sleep disturbance of cirrhotic patients, prevention of drug/poison induced liver toxicity,and prevention of post endoscopic retrograde cholangiopancreatography pancreatitis (PEP);more data is needed to recommend melatonin administration in the treatment of mentioned disorders.